Company: HCTI
Filing Date: 2025-04-22
Form Type: CORRESP
Source: 0001213900-25-034250
Chunk: 1

Company: Healthcare Triangle, Inc.
Filing Date: 2025-04-22
Form: CORRESP
Chunk 1
---
 by removing the references to "alternative cashless exercise" and exclusively using the term "zero                  
 exercise price" or another appropriate term that conveys that, in addition to the company receiving no cash upon the "alternative             
 cashless exercise," the warrant holders would be entitled to receive more shares than they would under the cash exercise terms.               |

Company Response:The Company acknowledges the Staff’s comment and has made the
requested additional disclosure on the cover page and on pages 4, 7, 9, 10, 11 and 12 the Amended Registration Statement.

U.S. Securities and Exchange Commission

April 22, 2025

Page 2

| 2. | Staff Comment: Please revise your cover page disclosure to highlight that the “alternative                                                 
 cashless exercise” provision would allow a Series B warrant holder to receive 3 shares of common stock without having to make any          
 exercise payment, and provide a materially complete discussion of the impact of such exercise on existing shareholders. Explain that as    
 a result you do not expect to receive any cash proceeds from the exercise of the Series B warrants because, if true, it is highly unlikely 
 that a warrant holder would wish to pay an exercise price to receive one share when they could choose the alternative cashless exercise    
 option and pay no money to receive 3 shares.                                                                                               |

Company Response: The Company acknowledges the Staff’s comment and has made the
requested additional disclosure on the cover page and on pages 4 and 9 of the Amended Registration Statement.

| 3. | Staff Comment: With reference to the disclosure on pages 8-9, please add a new risk                                                      
 factor to address potential dilution from the reset provision that could adjust upward the number of common shares underlying the Series 
 B Warrants. The risk factor should disclose the maximum number of shares that may be issuable upon exercise of the warrants.             |

Company Response: The Company has added the requested additional Risk Factor on page
5 of the Amended Registration Statement.

<div align='center'>* * * * *</div>

Please note that the Company has included certain changes in the Amended Registration
Statement other than those in response to the Staff’s comments.

Your prompt attention to the enclosed is greatly appreciated. If you have
any questions regarding this filing or the Company’s responses, please do not hesitate to contact me at (646) 844-1492 or Ross Carmel
of our office at (646) 838-1310.

Very truly